Resverlogix: Apabetalone Meets Primary Endpoint in a Pulmonary Arterial Hypertension Pilot Study



"In February 2020, Apabetalone became the first therapy of its kind to have been granted US FDA Breakthrough Therapy Designation, for a major cardiovascular indication, to help facilitate a time-efficient drug development program including planned clinical trials and plans for expediting the manufacturing development strategy."


SOURCE